top of page

poetvine Group

Public·11 members

Hector Karpov
Hector Karpov

Chris Survival Ver1.02.zip !NEW!


"I know what you're thinking, but I was born to survive the zombie apocalypse. My husband bought me this zombie-survival kit for Christmas. I have a machete, I know how to use it," the Grammy winner emphasized. "My songs are quite aggressive at times. I'm not afraid. I would know what to do. I was born for this."




Chris Survival Ver1.02.zip



but for judge this game... 4,5/5 map quite nice, arts chris not bad, honest this good one, the way you search item good, information how making items good, story not bad... but the enemy... WAY TOO EASY T-T) 'crying mood'


Cancer cachexia is a common, debilitating condition with limited therapeutic options. Using an established mouse model of lung cancer, we find that cachexia is characterized by reduced food intake, spontaneous activity, and energy expenditure accompanied by muscle metabolic dysfunction and atrophy. We identify Activin A as a purported driver of cachexia and treat with ActRIIB-Fc, a decoy ligand for TGF-β/activin family members, together with anamorelin (Ana), a ghrelin receptor agonist, to reverse muscle dysfunction and anorexia, respectively. Ana effectively increases food intake but only the combination of drugs increases lean mass, restores spontaneous activity, and improves overall survival. These beneficial effects are limited to female mice and are dependent on ovarian function. In agreement, high expression of Activin A in human lung adenocarcinoma correlates with unfavorable prognosis only in female patients, despite similar expression levels in both sexes. This study suggests that multimodal, sex-specific, therapies are needed to reverse cachexia.


In this study, we used the KL model to interrogate the changes in food intake, peripheral organ metabolism, and EE that occur following the induction of lung cancer. We found that mice with CACS have severely low TEE driven by reductions in food intake, spontaneous activity, and altered skeletal muscle metabolism. These changes correlated with high levels of tumor-derived Activin A and activation of the TGF-β/SMAD transcriptional program in the muscle. Based on this data, we hypothesized that CACS could be reversed by targeting both anorexia and Activin A-induced metabolic dysfunction. KL mice were treated with a ligand trap for TGF-β/activin family members (ActRIIB-Fc) in combination with agents that improve appetite (anti-GDF-15 antibody and anamorelin (Ana), a ghrelin receptor agonist). We found that only Ana increased food intake and fat mass, and the combination of Ana and ActRIIB-Fc further increased lean mass, restored spontaneous activity, and improved overall survival. These beneficial effects were limited to female mice and were dependent on ovarian function. In agreement, we found that high expression of Activin A in human lung adenocarcinoma correlates with unfavorable prognosis only in female patients, even though expression levels are similar in both sexes. Overall, our study suggests that multimodal, sex-specific, therapies are needed to reverse CACS.


A new classification of lung cancer was recently proposed by Lehtiö et al. based on tumor proteogenomic data59. Tumors from patients with lung cancer segregate into 6 molecular subtypes associated with specific immune-evasion mechanisms and therapeutic vulnerabilities. We found that Activin A was significantly high only in subtypes 4 and 6, two of the three subtypes with the worst survival (Fig. 6c). Interestingly, these subtypes are enriched in STK11/LKB1 mutations (subtype 4) and squamous cell carcinomas (subtype 6), which are both features of the KL model21. In the Lehtiö et al. data set, patients with high tumor levels of Activin A had worse survival (Fig. 6d), in agreement with data from the TCGA (Fig. 6e)60.


We found that blocking Activin A is only effective in female KL mice. Therefore, we searched the existing clinical databases for any evidence of sex-dependent effects of Activin A. Because Lehtio et al. is a relatively small sample, we used the TCGA data set. The TCGA allows segregation of the population by sex, and doing so reveals that only female patients have worse survival when Activin A gene expression is high in the tumor (Fig. 6f, g). Activin A expression in the tumor showed no sex difference at the mRNA (TCGA) or protein levels (Lehtio et al.), in agreement with the mouse model (Fig S7A). These data suggest that tumor-derived Activin A is associated with low BMI and poor prognosis in a sex-dependent manner in patients with lung cancer.


The changes to skeletal muscle and adipose tissue metabolism were associated with high levels of Activin A50,51. We identified increased tumor expression of Inhba and activation of the TGF-β/SMAD pathway in the skeletal muscle using unbiased transcriptomics. Activin A has been previously established as a pro-cachectic factor, and ActRIIB-Fc treatment is known to improve muscle mass and survival in cachectic mice bearing tumor allografts78,79,80,81,82. In KL mice, ActRIIB-Fc increased lean mass and spontaneous activity, but had no benefit on fat mass or survival unless it was given with an agent that effectively improved appetite (i.e., Ana). Ana therapy in isolation trended towards improved food intake and reversal of weight loss with no significant increase in survival. Similarly, RCTs in humans showed significant improvement in body weight and lean mass but no changes in overall survival. Considering the results of our study, we surmise that improved survival in humans could be achieved if Ana would be combined with agents that block cachectic factors like ActRIIB-Fc.


The beneficial effects of Ana/ActRIIB-Fc were limited to female mice. Sex discrepancies have been observed in other models of muscle wasting such as disuse atrophy and cardiac cachexia85,86,87. Still, this finding was surprising as Activin A is upregulated to the same degree in both male and female mice. Similarly, the expression of Activin A in human tumors is the same for both sexes yet, its impact on survival is only apparent in females. These data suggest that tumor-secreted Activin A is having sex-dependent effects on the host that lead to CACS. There are known differences in body composition, EE, and peripheral organ metabolism between men and women driven, in part, by sex hormones88. While peripheral estrogen receptor blockade with fulvestrant did not abrogate the response to the Ana-ActRIIB-Fc therapy, the surgical excision of the ovaries did. Activin A is known to stimulate the release of follicle stimulating hormone from the pituitary and control various ovarian functions, including follicular growth and development and ovarian steroidogenesis that could be playing a role in the sex dependent response to the combination therapy89. Additional studies are required to identify the specific role of the ovary in the response to the combination therapy.


Human CACS is a heterogenous condition with patients experiencing disparate degrees of anorexia, inflammation, and muscle wasting18,90. It is unclear which pre-clinical models best reflect each clinical subset. Here, we use existing clinical oncology databases to identify lung cancer subtypes that are best modeled by the KL mice. These subtypes (4 and 6 from Lehtio et al.59) have high levels of Activin A and poor overall survival. Future clinical studies could use the molecular features of these subtypes and blood Activin A levels as enrollment criteria. For example, there are late-stage clinical compounds available for the immediate translation of our findings. Ana was recently approved by the pharmaceutical regulatory authority of Japan for the treatment of patients with CACS, and bimagrumab, a fully human monoclonal antibody that prevents ligand binding to ActRIIB, is safe and increases lean mass in adults with sarcopenia and metabolic disease53,91,92. Our data suggests that the combination of Ana and bimagrumab would be effective in select patient populations.


The degree of survival improvement we observed with the Ana/ActRIIB-Fc therapy is on-par with the effects of chemotherapy and immunotherapy in this model yet, without impacting tumor growth93,94. These data highlight the power of multimodal therapy targeting both anorexia and peripheral organ dysfunction when they are both present. Future clinical studies could address the feasibility of this approach.


John Hudson FRGS is a Survival Instructor, Broadcaster, Writer, Public Speaker and Training Consultant whose specialist work takes him to some of the most remote and extreme environments in the world. Based in Cornwall, UK, John is the British military's chief SERE instructor and has been a resident expert on two series of Discovery's prime-time survival show: 'Survive That', a.k.a 'Dude You're Screwed'; putting his own resilience to the test on camera in front of millions. He created the UK Military's survival manual and is currently writing a new book about self-reliance and positive psychology for everyone.


ON THIS PAGE: You will find information about the number of people who are diagnosed with prostate cancer each year. You will also read general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see other pages.


The 5-year survival rate tells you what percent of people live at least 5 years after the cancer is found. Percent means how many out of 100. The 5-year survival rate for people with prostate cancer in the United States is 98%. The 10-year survival rate is also 98%. 041b061a72


Members

  • Hermann Romanov
    Hermann Romanov
  • Nick Neithan
    Nick Neithan
  • Hector Karpov
    Hector Karpov
  • Fazil Noses
    Fazil Noses
  • Эффект Доказан Экспертом
    Эффект Доказан Экспертом
  • Instagram

Thanks for submitting!

© 2019–2027 by Tatyana Desvarieux

bottom of page